Entrada Therapeutics (TRDA) Total Liabilities (2020 - 2026)

Entrada Therapeutics' Total Liabilities history runs 7 years deep, the most recent figure standing at $64.7 million for Q1 2026.

• In Q1 2026, Total Liabilities fell 6.58% year-over-year to $64.7 million; the TTM figure through Mar 2026 stood at $64.7 million (down 6.58% YoY), while the FY2025 annual figure was $71.2 million, down 27.04% from the prior year.
• Total Liabilities was $64.7 million for Q1 2026 at Entrada Therapeutics, down from $71.2 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $287.1 million in Q2 2023 to a low of $39.3 million in Q1 2022.
• Historically, Total Liabilities has averaged $125.2 million across 5 years, with a median of $72.2 million in 2025.
• The sharpest annual moves came in 2023 and 2025: Total Liabilities soared 619.88% in 2023, then sank 71.34% in 2025.
• A 5-year view of Total Liabilities shows it stood at $39.5 million in 2022, then surged by 474.23% to $226.8 million in 2023, then tumbled by 56.95% to $97.6 million in 2024, then fell by 27.04% to $71.2 million in 2025, then decreased by 9.24% to $64.7 million in 2026.
• The last three Total Liabilities figures came in at $64.7 million (Q1 2026), $71.2 million (Q4 2025), and $72.2 million (Q3 2025), per Business Quant data.